C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.L16586, L16606
This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction of the immune system. The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.L16586, L16606
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Etonogestrel | The risk or severity of thromboembolism can be increased when Etonogestrel is combined with Human C1-esterase inhibitor. |
| Desogestrel | The risk or severity of thromboembolism can be increased when Desogestrel is combined with Human C1-esterase inhibitor. |
| Megestrol acetate | The risk or severity of thromboembolism can be increased when Megestrol acetate is combined with Human C1-esterase inhibitor. |
| Levonorgestrel | The risk or severity of thromboembolism can be increased when Levonorgestrel is combined with Human C1-esterase inhibitor. |
| Dydrogesterone | The risk or severity of thromboembolism can be increased when Dydrogesterone is combined with Human C1-esterase inhibitor. |
| Progesterone | The risk or severity of thromboembolism can be increased when Progesterone is combined with Human C1-esterase inhibitor. |
| Medroxyprogesterone acetate | The risk or severity of thromboembolism can be increased when Medroxyprogesterone acetate is combined with Human C1-esterase inhibitor. |
| Norethisterone | The risk or severity of thromboembolism can be increased when Norethisterone is combined with Human C1-esterase inhibitor. |
| Ethynodiol diacetate | The risk or severity of thromboembolism can be increased when Ethynodiol diacetate is combined with Human C1-esterase inhibitor. |
| Norgestimate | The risk or severity of thromboembolism can be increased when Norgestimate is combined with Human C1-esterase inhibitor. |
| Drospirenone | The risk or severity of thromboembolism can be increased when Drospirenone is combined with Human C1-esterase inhibitor. |
| Allylestrenol | The risk or severity of thromboembolism can be increased when Allylestrenol is combined with Human C1-esterase inhibitor. |
| Cyproterone acetate | The risk or severity of thromboembolism can be increased when Cyproterone acetate is combined with Human C1-esterase inhibitor. |
| Norelgestromin | The risk or severity of thromboembolism can be increased when Norelgestromin is combined with Human C1-esterase inhibitor. |
| Gestodene | The risk or severity of thromboembolism can be increased when Gestodene is combined with Human C1-esterase inhibitor. |
| Hydroxyprogesterone caproate | The risk or severity of thromboembolism can be increased when Hydroxyprogesterone caproate is combined with Human C1-esterase inhibitor. |
| Dienogest | The risk or severity of thromboembolism can be increased when Dienogest is combined with Human C1-esterase inhibitor. |
| Medrogestone | The risk or severity of thromboembolism can be increased when Medrogestone is combined with Human C1-esterase inhibitor. |
| Norethynodrel | The risk or severity of thromboembolism can be increased when Norethynodrel is combined with Human C1-esterase inhibitor. |
| Norgestrel | The risk or severity of thromboembolism can be increased when Norgestrel is combined with Human C1-esterase inhibitor. |
| Altrenogest | The risk or severity of thromboembolism can be increased when Altrenogest is combined with Human C1-esterase inhibitor. |
| Gestrinone | The risk or severity of thromboembolism can be increased when Gestrinone is combined with Human C1-esterase inhibitor. |
| Nomegestrol | The risk or severity of thromboembolism can be increased when Nomegestrol is combined with Human C1-esterase inhibitor. |
| Lynestrenol | The risk or severity of thromboembolism can be increased when Lynestrenol is combined with Human C1-esterase inhibitor. |
| Gestonorone | The risk or severity of thromboembolism can be increased when Gestonorone is combined with Human C1-esterase inhibitor. |
| Chlormadinone | The risk or severity of thromboembolism can be increased when Chlormadinone is combined with Human C1-esterase inhibitor. |
| Methylestrenolone | The risk or severity of thromboembolism can be increased when Methylestrenolone is combined with Human C1-esterase inhibitor. |
| Norgestrienone | The risk or severity of thromboembolism can be increased when Norgestrienone is combined with Human C1-esterase inhibitor. |
| Promegestone | The risk or severity of thromboembolism can be increased when Promegestone is combined with Human C1-esterase inhibitor. |
| Quingestanol | The risk or severity of thromboembolism can be increased when Quingestanol is combined with Human C1-esterase inhibitor. |
| Demegestone | The risk or severity of thromboembolism can be increased when Demegestone is combined with Human C1-esterase inhibitor. |
| Etynodiol | The risk or severity of thromboembolism can be increased when Etynodiol is combined with Human C1-esterase inhibitor. |
| Nomegestrol acetate | The risk or severity of thromboembolism can be increased when Nomegestrol acetate is combined with Human C1-esterase inhibitor. |
| Hydroxyprogesterone | The risk or severity of thromboembolism can be increased when Hydroxyprogesterone is combined with Human C1-esterase inhibitor. |
| Norethindrone enanthate | The risk or severity of thromboembolism can be increased when Norethindrone enanthate is combined with Human C1-esterase inhibitor. |
| Quingestanol acetate | The risk or severity of thromboembolism can be increased when Quingestanol acetate is combined with Human C1-esterase inhibitor. |
| Algestone acetophenide | The risk or severity of thromboembolism can be increased when Algestone acetophenide is combined with Human C1-esterase inhibitor. |